27571 Dupilumab provides clinically meaningful responses in adults with moderate-to-severe atopic dermatitis (AD): Results from LIBERTY AD CHRONOS study

Background: AD, a common chronic skin condition, has substantial impact on health-related quality of life (HRQoL). Stringent regulatory endpoints of Investigator Global Assessment score 0/1 and 75% reduction in Eczema Area and Severity Index (EASI-75) capture the AD skin lesion component, without encompassing all clinical endpoints. More inclusive tools are often needed to assess clinically meaningful responses in AD patients. We assess the effect of 52-week dupilumab treatment on a composite endpoint incorporating improvement in AD signs (EASI-75), symptoms (Peak Pruritus Numerical Rating Scale[PP-NRS] score≤4), and HRQoL (Dermatology Life Quality Index[DLQI]≤5) in adult AD patients.